Table 5.
Results of Baseline L-GaN Control for S1.
| BG level, mg/dL | Status | WM3: CGM data (actual insulin; September 23), % | S1: reference (WM3 insulin; September 23), % | S1 (I) (September 23 + 10 days), % | S1 (No I) (September 23 + 10 days), % |
|---|---|---|---|---|---|
| 160+ | Hyperglycemia and near hyperglycemia | 90.3 | 65.4 | ||
| 140-160 | High intermediate | 9.7 | 20.6 | ||
| 120-140 | Desired prandial | 14.0 | 24.2 | 42.5 | |
| 80-120 | Desired basal and prandial | 75.8 | 57.5 | ||
| 70-80 | Low intermediate | ||||
| 0-70 | Hypoglycemia |
WM3’s and S1’s values under WM3’s insulin regime (shaded) are included for comparison. BG, blood glucose; CGM, continuous glucose monitoring); I, scenario where plasma insulin assays are available in Stage 1 identification; L-GaN, Lyapunov-based Game against Nature; (No I), scenario where plasma insulin assays are unavailable. Bold text and numbers pertain to the desired target interval for blood glucose values.